Kathryn Cavanaugh is a Partner at Grace Beauty Capital, an early stage venture capital firm focused on investing in emerging digital brands, consumer and retail technology companies. She has been investing in and advising in early stage companies for the last twelve years in the Healthcare, Technology and Consumer sectors. From 2005-2010, Kathryn worked for De Novo Ventures, a top quartile $650M healthcare fund, where she sourced, evaluated and executed $200M of equity investments in early to late stage healthcare companies. She also led West Coast deal sourcing for Sightline Partners, a direct secondary fund focused on early stage healthcare companies. In addition, Kathryn worked for Mainsail Partners, a lower middle market growth buyout fund, serving as their VP of Talent and a Board Director for The Bar Method, Inc, a Mainsail portfolio company. She also served as an interim Senior Executive with The Bar Method, joining after Mainsail exited their position in 2015. She began her career as a Senior Process Engineer with Merck & Co., Inc., working in the US, Europe and Asia from 1997-2003. Kathryn is a graduate of the University of Notre Dame with Bachelor of Science degrees in Chemical Engineering and Biochemistry and holds an M.B.A. from Harvard Business School.